Personalizing lung cancer prevention through a reverse migration strategy.

[1]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[2]  Gerald C. Chu,et al.  Proinvasion metastasis drivers in early-stage melanoma are oncogenes. , 2011, Cancer cell.

[3]  Edward S. Kim,et al.  The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration , 2011, Cancer Prevention Research.

[4]  R. Elashoff,et al.  Lung Cancer Chemoprevention with Celecoxib in Former Smokers , 2011, Cancer Prevention Research.

[5]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[6]  M. Meyerson,et al.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.

[7]  E. Dmitrovsky,et al.  Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models , 2011, Cancer Prevention Research.

[8]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[9]  Y. Miller,et al.  Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers , 2011, Cancer Prevention Research.

[10]  S. Lippman,et al.  Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Edward S. Kim,et al.  Abstract 3674: Gene expression analysis of field of cancerization in early stage NSCLC patients towards development of biomarkers for personalized prevention , 2011 .

[12]  D. Bickers,et al.  Abstract LB-1: An investigator-initiated, phase II randomized, double-blind, placebo-controlled trial of GDC-0449 for prevention of BCCs in basal cell nevus syndrome (BCNS) patients.gg , 2011 .

[13]  M. Ladanyi,et al.  Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[15]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[16]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[17]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[18]  J. Jett,et al.  A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Marks,et al.  A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[21]  Adam M. Gustafson,et al.  Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development , 2010, Science Translational Medicine.

[22]  Edward S. Kim,et al.  Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers , 2010, Cancer Prevention Research.

[23]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[24]  C I Amos,et al.  Re: Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. , 2009, Journal of the National Cancer Institute.

[25]  Raoul Tibes,et al.  Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. , 2009, The New England journal of medicine.

[26]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[27]  B. Skov,et al.  Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. , 2009 .

[28]  J. Subramanian,et al.  Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005 , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  R. Góralczyk.  ß-Carotene and Lung Cancer in Smokers: Review of Hypotheses and Status of Research , 2009, Nutrition and cancer.

[30]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Pirker,et al.  EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.

[32]  S. Lippman,et al.  Cancer prevention: from 1727 to milestones of the past 100 years. , 2009, Cancer research.

[33]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[34]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.

[35]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[36]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[37]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[38]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[39]  I. Wistuba,et al.  Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas , 2008, Cancer Prevention Research.

[40]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  W. Foulkes.  p53--master and commander. , 2007, The New England journal of medicine.

[43]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[44]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[45]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[46]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[47]  Thomas J. Smith,et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  P. Sebastiani,et al.  Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer , 2007, Nature Medicine.

[49]  I. Wistuba.  Genetics of preneoplasia: lessons from lung cancer. , 2007, Current molecular medicine.

[50]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[51]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[52]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[53]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[54]  K. Uematsu,et al.  Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. , 2006, Lung cancer.

[55]  M. Meyerson,et al.  Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Herman,et al.  Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. , 2006, Cancer research.

[57]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[58]  P. Hainaut,et al.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.

[59]  Li Mao,et al.  Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Edward S. Kim,et al.  Chemoprevention of lung cancer , 2004, Journal of the Medical Association of Georgia.

[61]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[63]  C. Harris,et al.  Tobacco Carcinogen-Induced Cellular Transformation Increases Activation of the Phosphatidylinositol 3′-Kinase/Akt Pathway in Vitro and in Vivo , 2004, Cancer Research.

[64]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[65]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[66]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[67]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[68]  J. Goergen,et al.  The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism , 2001, EMBO reports.

[69]  S. Lippman,et al.  Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. , 2001, Journal of the National Cancer Institute.

[70]  S. Lippman,et al.  Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[72]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[73]  O. Dalesio,et al.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. , 2000, Journal of the National Cancer Institute.

[74]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[75]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[76]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[77]  M. Paolini,et al.  Co-carcinogenic effect of β-carotene , 1999, Nature.

[78]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[79]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[80]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[81]  J S Lee,et al.  Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.

[82]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[83]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[84]  M. Volm,et al.  Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. , 1996, British Journal of Cancer.

[85]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[86]  P. Thomas,et al.  Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1990, The Annals of thoracic surgery.

[87]  W. Hong,et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.

[88]  E. Bergstralh,et al.  Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. , 1984, The Annals of thoracic surgery.

[89]  M. Sporn,et al.  Can dietary beta-carotene materially reduce human cancer rates? , 1981, Nature.

[90]  M. Sporn,et al.  Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). , 1976, Federation proceedings.

[91]  E. C. Hammond,et al.  Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. , 1961, The New England journal of medicine.

[92]  O. Auerbach,et al.  Carcinoma-in-situ and early invasive carcinoma occurring in the tracheobronchial trees in cases of bronchial carcinoma. , 1957, The Journal of thoracic surgery.

[93]  O. Auerbach,et al.  Changes in the bronchial epithelium in relation to smoking and cancer of the lung; a report of progress. , 1957, The New England journal of medicine.

[94]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.

[95]  P. Rous,et al.  THE CARCINOGENIC EFFECT OF A PAPILLOMA VIRUS ON THE TARRED SKIN OF RABBITS : I. DESCRIPTION OF THE PHENOMENON. , 1938, The Journal of experimental medicine.

[96]  P. Rous,et al.  THE CARCINOGENIC EFFECT OF A PAPILLOMA VIRUS ON THE TARRED SKIN OF RABBITS , 1938, The Journal of experimental medicine.

[97]  L. Tanoue.  Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .

[98]  L. Tanoue,et al.  Molecular Origins of Cancer. Lung Cancer , 2010 .

[99]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[100]  K. Seibert,et al.  Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[101]  S. Z. Abdel‐Rahman,et al.  Co-carcinogenic effect of beta-carotene. , 1999, Nature.

[102]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[103]  J. Ingle,et al.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.